Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Authors: Bo Åhrén, Luís Masmiquel, Harish Kumar, Mehmet Sargın, Julie Derving Karsbøl, Sanja Hald Jacobsen, Francis Chun Chung Chow - The Lancet 2017 cited by 476